These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22124372)

  • 1. Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration.
    Trüe O; Matthias P
    Immunol Cell Biol; 2012 Jan; 90(1):78-84. PubMed ID: 22124372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of naturally occurring histone deacetylase inhibitors.
    Kim B; Hong J
    Curr Top Med Chem; 2015; 14(24):2759-82. PubMed ID: 25487010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors and cell death.
    Zhang J; Zhong Q
    Cell Mol Life Sci; 2014 Oct; 71(20):3885-901. PubMed ID: 24898083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay between histone deacetylases and rho kinases is important for cancer and neurodegeneration.
    Mertsch S; Krämer OH
    Cytokine Growth Factor Rev; 2017 Oct; 37():29-45. PubMed ID: 28606734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylases as targets for the treatment of human neurodegenerative diseases.
    D'Mello SR
    Drug News Perspect; 2009 Nov; 22(9):513-24. PubMed ID: 20072728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
    Saha RN; Pahan K
    Cell Death Differ; 2006 Apr; 13(4):539-50. PubMed ID: 16167067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
    Gediya P; Parikh PK; Vyas VK; Ghate MD
    Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy.
    Patra S; Panigrahi DP; Praharaj PP; Bhol CS; Mahapatra KK; Mishra SR; Behera BP; Jena M; Bhutia SK
    Cell Mol Life Sci; 2019 Sep; 76(17):3263-3282. PubMed ID: 30982077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
    Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, Functions and Selective Inhibitors of HDAC6.
    Liang T; Fang H
    Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
    Simões-Pires C; Zwick V; Nurisso A; Schenker E; Carrupt PA; Cuendet M
    Mol Neurodegener; 2013 Jan; 8():7. PubMed ID: 23356410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Feb; 243():117278. PubMed ID: 31926248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human neuronal cells: epigenetic aspects.
    Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
    Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
    Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of histone deacetylases (HDACs) in UPR regulation.
    Kahali S; Sarcar B; Chinnaiyan P
    Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple roles of HDAC inhibition in neurodegenerative conditions.
    Chuang DM; Leng Y; Marinova Z; Kim HJ; Chiu CT
    Trends Neurosci; 2009 Nov; 32(11):591-601. PubMed ID: 19775759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting histone deacetylases: Emerging applications beyond cancer.
    Raouf YS
    Drug Discov Today; 2024 Sep; 29(9):104094. PubMed ID: 38997001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
    Batchu SN; Brijmohan AS; Advani A
    Clin Sci (Lond); 2016 Jun; 130(12):987-1003. PubMed ID: 27154743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.